Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RC18 in Relapsing Remitting Multiple Sclerosis
NCT04625153Phase 2Terminated
- Sponsor
- RemeGen
- Start
- May 2021
- Primary completion
- Apr 2026
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of telitacicept in multiple sclerosis (MS), sponsored by RemeGen. Started May 2021; status: terminated.
02
Drugs
telitacicept
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04625153.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04625153.